Year: 2012
Type: review
Abstract: The emphasis in human pluripotent stem cell (hPSC) technologies has shifted from cell therapy to in vitro disease modelling and drug screening. This review examines why this shift has occurred, and how current technological limitations might be overcome to fully realise the potential of hPSCs. Details are provided for all disease-specific human induced pluripotent stem cell lines spanning a dozen dysfunctional organ systems. Phenotype and pharmacology have been examined in only 17 of 63 lines, primarily those that model neurological and cardiac conditions. Drug screening is most advanced in hPSC-cardiomyocytes. Responses for almost 60 agents include examples of how careful tests in hPSC-cardiomyocytes have improved on existing in vitro assays, and how these cells have been integrated into high throughput imaging and electrophysiology industrial platforms. Such successes will provide an incentive to overcome bottlenecks in hPSC technology such as improving cell maturity and industrial scalability whilst reducing cost.
Source: BioEssays
Institution: University of Nottingham
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $5,330
Awards: Stem cell screening of human nutrient-gene interactions at the epigenetic level, A novel system for perfusion and real-time analysis of single hESC-derived cardiomyocytes, Developing scalable and standardised manufacturing methods for human pluripotent stem cells, New in vitro models of long QT syndrome by coupling induced pluripotency and cardiomyocyte differentiation, G6158637280
OpenAlex ID: W2169114436
